Patents by Inventor Russell R. Ferlita

Russell R. Ferlita has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline forms of an inhibitor of 11-?-hydroxysteroid dehydrogenase type 1
    Patent number: 8618112
    Abstract: Novel crystalline salts of 3-[4-(3-ethanesulfonyl-propyl)-bicyclo[2.2.2]oct-1-yl]-4-methyl-5-(2-trifluoromethyl-phenyl)-4H-1,2,4-triazole are potent inhibitors of 11?-hydroxysteroid dehydrogenase Type 1 and are useful for the treatment of conditions associated with Metabolic Syndrome as well as cognitive impairment. The invention also relates to pharmaceutical compositions containing these novel salts, processes to prepare these salts and their pharmaceutical compositions as well as uses thereof for the treatment of Type 2 diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, and cognitive impairment.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: December 31, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Joseph E. Lynch, Yuri Y. Bereznitski, Frederick T. Mattrey, John L. Leazer, Jr., Russell R. Ferlita, Jinchu Liu, Jungjun Yin, Robert M. Wenslow, Jr.
  • Crystalline forms of MC4R agonist and process for synthesis
    Patent number: 8129413
    Abstract: The present invention relates to a process for producing N-{(1S)-1-[2-(1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}acetamide, and novel crystalline salts, hydrates, solvates, and polymorphic forms thereof.
    Type: Grant
    Filed: June 23, 2006
    Date of Patent: March 6, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Ralph Calabria, Yu Cheng, Russell R. Ferlita, Ashkan Kamali, Jerry A. Murry, David Mathre, Andrey V. Peresypkin, Karen Thompson, Jian Wang, Robert M. Wenslow
  • NOVEL CRYSTALLINE FORMS OF AN INHIBITOR OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1
    Publication number: 20110237634
    Abstract: Novel crystalline salts of 3-[4-(3-ethanesulfonyl-propyl)-bicyclo[2.2.2]oct-1-yl]-4-methyl-5-(2-trifluoromethyl-phenyl)-4H-1,2,4-triazole are potent inhibitors of 11?-hydroxysteroid dehydrogenase Type 1 and are useful for the treatment of conditions associated with Metabolic Syndrome as well as cognitive impairment. The invention also relates to pharmaceutical compositions containing these novel salts, processes to prepare these salts and their pharmaceutical compositions as well as uses thereof for the treatment of Type 2 diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, and cognitive impairment.
    Type: Application
    Filed: December 7, 2009
    Publication date: September 29, 2011
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Joseph E. Lynch, Yuri Y. Bereznitski, Frederick T. Mattrey, John L. Leazer, JR., Russell R. Ferlita, Jinchu Liu, Jungjun Yin, Robert M. Wenslow, JR.
  • Synthesis and crystalline forms of NPY5 antagonist
    Patent number: 7700611
    Abstract: The present invention relates to a process for producing crystalline trans-N-[1-(2-fluorophenyl)-S-pyrazoly]-3-ox-ospiro[6-azaisobenzofuran-1(3H),1?-cyclohexane]-4?-carboxamide and novel salts, hydrates and polymorphs thereof.
    Type: Grant
    Filed: July 24, 2006
    Date of Patent: April 20, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Russell R. Ferlita, Yuji Haga, Makoto Ishikawa, Keisuke Kamei, Shinji Kato, Hisaki Kojima, Aaron Moment, Nobuaki Nonoyama, Nobuya Satake, Kazuki Shigemori, Toshihiro Wada, Yaling Wang, Steven A. Weissman, Robert M. Wenslow
  • Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
    Patent number: 7612072
    Abstract: The present invention relates to a novel amorphous form of the dihydrogenphosphate salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-?]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine of structural formula I as well as a process for its preparation, pharmaceutical compositions containing this novel form, and methods of use of the novel form and pharmaceutical compositions for the treatment of diabetes, obesity, and high blood pressure.
    Type: Grant
    Filed: September 9, 2005
    Date of Patent: November 3, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Russell R. Ferlita, Robert M. Wenslow
  • Crystalline forms of mc4r agonist and process for synthesis
    Publication number: 20090233967
    Abstract: The present invention relates to a process for producing N-{(1S)-1-[2-(1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}acetamide, and novel crystalline salts, hydrates, solvates, and polymorphic forms thereof.
    Type: Application
    Filed: June 23, 2006
    Publication date: September 17, 2009
    Inventors: Ralph Calabria, Yu Cheng, Russell R. Ferlita, Ashkan Kamali, Jerry A. Murry, David Mathre, Andrey V. Peresypkin, Karen Thompson, Jian Wang, Robert M. Wenslow
  • Synthesis and Crystalline Forms of Npy5 Antagonist
    Publication number: 20090124648
    Abstract: The present invention relates to a process for producing crystalline trans-N-[1-(2-fluorophenyl)-S-pyrazoly]-3-ox-ospiro[6-azaisobenzofuran-1(3H),1?-cyclohexane]-4?-carboxamide and novel salts, hydrates and polymorphs thereof.
    Type: Application
    Filed: July 24, 2006
    Publication date: May 14, 2009
    Inventors: Russell R. Ferlita, Yuji Haga, Makoto Ishikawa, Keisuke Kamei, Shinji Kato, Hisaki Kojima, Aaron Moment, Nobuaki Nonoyama, Nobuya Satake, Kazuki Shigemori, Toshihiro Wada, Yaling Wang, Steven A. Weissman, Robert M. Wenslow
  • Novel Crystalline Salts of a Dipeptidyl Peptidase-IV Inhibitor
    Publication number: 20080227786
    Abstract: Novel crystalline salts of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-&agr; amine are potent inhibitors of dipeptidyl peptidase-IV and are useful for the treatment of non-insulin dependent (Type 2) diabetes mellitus. The invention also relates to pharmaceutical compositions containing these novel salts, processes to prepare these salts and their pharmaceutical compositions as well as uses thereof for the treatment of Type 2 diabetes.
    Type: Application
    Filed: January 12, 2005
    Publication date: September 18, 2008
    Inventors: Russell R. Ferlita, Karl Hansen, Vicky K. Vydra, Yaling Wang, Christopher M. Lindemann
  • Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
    Patent number: 7326708
    Abstract: The dihydrogenphosphate salt of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine is a potent inhibitor of dipeptidyl peptidase-IV and is useful for the prevention and/or treatment of non-insulin dependent diabetes mellitus, also referred to as type 2 diabetes. The invention also relates to a crystalline monohydrate of the dihydrogenphosphate salt as well as a process for its preparation, pharmaceutical compositions containing this novel form and methods of use for the treatment of diabetes, obesity, and high blood pressure.
    Type: Grant
    Filed: June 23, 2004
    Date of Patent: February 5, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Stephen Howard Cypes, Alex Minhua Chen, Russell R. Ferlita, Karl Hansen, Ivan Lee, Vicky K. Vydra, Robert M. Wenslow, Jr.
  • Hydrohalide salts of an HIV protease inhibitor
    Publication number: 20030125336
    Abstract: Pharmaceutically acceptable hydrochloride and hydrobromide salts of Compound A are disclosed, wherein Compound A is of formula: 1
    Type: Application
    Filed: May 30, 2002
    Publication date: July 3, 2003
    Inventors: Fred J. Fleitz, Daniel E. Petrillo, Yaling Wang, Russell R. Ferlita, David C. Dubost, Joseph D. Armstrong